Literature DB >> 12719971

Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide.

Elke De Wachter1, Jesse Vanbesien2, Iris De Schutter1, Anne Malfroot1, Jean De Schepper3.   

Abstract

UNLABELLED: A 4-year-old boy with cystic fibrosis developed hypertension, rapid weight gain and a moon face 2 weeks after starting a combined treatment of oral itraconazole and inhaled budesonide for a suspected allergic bronchopulmonary aspergillosis. Adrenal suppression was documented and found to persist 3 months after stopping this combined treatment.
CONCLUSION: To the best of our knowledge, this is the first time that an iatrogenic Cushing syndrome in a young child with cystic fibrosis after such combined treatment is reported. The inhibition of cytochrome P4503A by intraconazole and a higher glucocorticoid tissue sensitivity is suggested as the underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719971     DOI: 10.1007/s00431-003-1233-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  [Iatrogenic Cushing syndrome in infants. Report of a case with dwarfism].

Authors:  M Petrus; J C Netter; F Rance; R Chateauneuf; G Bildstein; C Cabalet; J Sermet; A Delprat
Journal:  Ann Pediatr (Paris)       Date:  1990-01

2.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.

Authors:  B Lebrun-Vignes; V C Archer; B Diquet; J C Levron; O Chosidow; A J Puech; D Warot
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

3.  Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.

Authors:  M Skov; K M Main; I B Sillesen; J Müller; C Koch; S Lanng
Journal:  Eur Respir J       Date:  2002-07       Impact factor: 16.671

4.  Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects.

Authors:  M Panarelli; C D Holloway; R Fraser; J M Connell; M C Ingram; N H Anderson; C J Kenyon
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

5.  Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.

Authors:  J S Parmar; T Howell; J Kelly; D Bilton
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

6.  Unexpected side-effects of inhaled steroids: a case report.

Authors:  K Priftis; M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 7.  Glucocorticoid receptor variants: clinical implications.

Authors:  R H DeRijk; M Schaaf; E R de Kloet
Journal:  J Steroid Biochem Mol Biol       Date:  2002-06       Impact factor: 4.292

Review 8.  A review of developmental aspects of cytochrome P450.

Authors:  J R Oesterheld
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

9.  Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids.

Authors:  R J Perry; C A Findlay; M D C Donaldson
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

10.  Temporary inhibition of growth and adrenal suppression associated with the use of steroid nose drops.

Authors:  C E Daman Willems; R Dinwiddie; D B Grant; R P Rivers; M Zahir
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

View more
  6 in total

Review 1.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

Review 2.  Glucocorticoid-induced hypertension.

Authors:  Julie E Goodwin; David S Geller
Journal:  Pediatr Nephrol       Date:  2011-07-09       Impact factor: 3.714

3.  Severe arterial hypertension: a possible complication of McCune-Albright syndrome.

Authors:  Yasuhisa Ohata; Takehisa Yamamoto; Ikuko Mori; Toru Kikuchi; Toshimi Michigami; Yasuo Imanishi; Kenichi Satomura; Shinobu Ida; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

Review 4.  Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects.

Authors:  Camilla Christensson; Anders Thorén; Bengt Lindberg
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Benefits of antifungal therapy in asthma patients with airway mycosis: A retrospective cohort analysis.

Authors:  Evan Li; Chu-Lin Tsai; Zahida K Maskatia; Ekta Kakkar; Paul Porter; Roger D Rossen; Sarah Perusich; John M Knight; Farrah Kheradmand; David B Corry
Journal:  Immun Inflamm Dis       Date:  2018-03-25

6.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.